Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma
Authors:
Open Access
Abstract
BACKGROUND The carboplatin‐based chemotherapeutic regimen M‐CAVI (methotrexate, carboplatin, and vinblastine) is active against bladder carcinoma and can be administered to patients who are ineligible to receive cisplatin or doxorubicin. The authors designed a randomized study to evaluate whether M‐CAVI offers a therapeutic advantage over the cisplatin‐based regimen M‐VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) in the treatment of patients with surgically incurable advanced bladder carcinoma. METHODS Patients with surgically incurable advanced bladder carcinoma were enrolled on a randomized trial comparing M‐CAVI, which consists of carboplatin (300 mg/m2 on Day 2, adjusted using Calvert's formula for an area under the curve of 5), methotrexate (30 mg/m2 on Days 1, 15, and 22), and vinblastine (3 mg/m2 on Days 2, 15, and 22) administered every 28 days, versus standard M‐VAC. The eligibility criteria included histologically proven bladder carcinoma, surgically incurable disease, and no prior chemotherapy. Patients were treated until disease progression or unacceptable toxicity occurred. RESULTS From January 1989 to January 1994, 47 assessable patients were included. Seventeen patients had lymph node disease and 30 had distant metastatic disease. Twenty‐three patients were randomized to receive M‐CAVI and 24 to receive M‐VAC. Patient characteristics in the two groups were similar. Overall response rates were 39% (95% confidence interval [CI], 20‐62%) for M‐CAVI and 52% (95% CI, 30‐73%) for M‐VAC (P = 0.3), with 3 complete responses observed among patients treated with M‐VAC and none among those in the M‐CAVI group. M‐VAC was associated with more gastrointestinal toxicity, stomatitis, alopecia, and Grade 4 neutropenia than M‐CAVI. One toxicity‐related death occurred in the M‐VAC group. There was a statistically significant difference in median disease‐related survival time favoring M‐VAC (16 months; range, 6 to 22+) versus M‐CAVI (9 months; range, 6 to 14+) (P = 0.03). CONCLUSIONS M‐CAVI is less toxic but less active than M‐VAC in the treatment of patients with advanced bladder carcinoma. Carboplatin‐based regimens in which carboplatin is administered at the dose range used in the current study should be reserved for patients who cannot tolerate cisplatin treatment. Further research is required to assess the impact of high dose carboplatin in the treatment of this disease. Cancer 1997; 80:1966‐72. © 1997 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of Clinical Oncology, 1992
- A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.Journal of Clinical Oncology, 1990
- Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseCancer, 1989
- Cisplatin, Cyclophosphamide and Doxorubicin Chemotherapy for Unresectable Urothelial Tumors: The M. D. Anderson ExperienceJournal of Urology, 1989
- Chemotherapy of urothelial tract tumorsCancer, 1987
- Phase III Comparison of Cisplatin Alone Versus Cisplatin, Doxorubicin and Cyclophosphamide in the Treatment of Bladder (Urothelial) Cancer: A Southeastern Cancer Study Group TrialJournal of Urology, 1987
- Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.Journal of Clinical Oncology, 1985
- Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1985
- Cis-Diamminedichloride Platinum II in the Treatment of Abvanced Bladder CancerJournal of Urology, 1980
- Cis-Diamminebichloroplatinum as a Therapeutic Agent in Metastatic Transitional Cell CarcinomaJournal of Urology, 1980